An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Alpine Immune Sciences Announces Participation in September Investor Conferences
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
SEATTLE--(BUSINESS WIRE)--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of its management team will present at the following investor conferences in September 2021:
H.C. Wainwright 23rd Annual Global Investment Conference Date: Monday, September 13, 2021 Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT Event: Company Presentation
Oppenheimer Fall Healthcare Summit
Date: Monday, September 20, 2021 Time: 2:55 p.m. ET/11:55 a.m. PT Event: Fireside Chat
Cantor Global Healthcare Conference Date: Wednesday, September 29, 2021 Time: 2:00 p.m. ET/11:00 a.m. PT Event: Company Presentation
Webcasts of the H.C. Wainwright, Oppenheimer, and Cantor presentations will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of the presentations will be available on the company website for 90 days following the webcast.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.
Investor Relations
Alex Sharif Director, Investor Relations and Corporate Development
Alpine Immune Sciences, Inc. 206-788-4545
ir@alpineimmunesciences.com
founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.
